Острая склеродермическая нефропатия: есть ли надежда на перемены?


Обсуждаются клинические, патогенетические и прогностические особенности острой склеродермической нефропатии, а также подходы к ее лечению.


1. Guerini S., Cavazzana I., Venturelli C. et al. Renal involvement in systemicsclerosis. G. Ital. Nefrol. 2007; 24(4): 295–310.

2. Teixeira L., Servettaz A., Mehrenberger M. Scleroderma renal crisis. PresseMed. 2006; 35 (12 Pt. 2): 1966–1974.

3. Horn H.C., Otte K.E., Jensen J.E. Renal crisis at the onset of systemicsclerosis. Ugeskr Laeger. 2003; 165(40): 3832.

4. Canet J.J., Castane J., Alvarez M. et al. Scleroderma renal crisis sinescleroderma. Nephron. 2002; 90(1): 119–120.

5. Steen V.D. Renal involvement in systemic sclerosis. Clin. Dermatol. 1994;12: 253–258.

6. Steen V.D. Scleroderma renal crisis. Rheum. Dis. Clin. North Am. 2003;29(2): 315–333.

7. Reveille J.D., Owerbach D., Goldstein R. et al. Association of polar aminoacids at position 26 of the HLA-DQB1 first domain with the anticentromereautoantibody response in systemic sclerosis (scleroderma). J. Clin. Invest.1992; 89: 1208–1213.

8. Steen V. Scleroderma renal crisis. Indian J. Med. Sci. 2007;61(1): 71–72.

9. Jimenez S.A., Derk C.T. Following the molecular pathways toward anunderstanding of the pathogenesis of systemic sclerosis. Ann. Intern. Med.2004; 140: 37–50.

10. Gϋndϋs O.H., Fertig N., Lucas M. et al. Systemic sclerosis with renalcrisis and pulmonary hypertension: a report of eleven cases. Arthritis andRheumatism. 2001; 44(7): 1663–1666.

11. Codullo V., Cavazzana I., Bonino C. et al. Serologic profile and mortalityrates of scleroderma renal crisis in Italy. J. Rheumatol. 2009; 36(7):1464–1469.

12. Brown A.N., Bolster M.B. Scleroderma renal crisis in pregnancy associatedwith massive proteinuria. Clin. Exp. Rheumatol. 2003; 21(1): 114–116.

13. Celikbilek M., Elsurer R., Afsar B. et al. Mixed connective tissue disease:a case with scleroderma renal crisis following abortion. Clin. Rheumatol.2007; 26(9): 1545–1547.

14. Szigeti N., Fabian G., Czirjak L. Fatal scleroderma renal crisis caused bygastrointestinal bleeding in a patient with scleroderma, Sjogrencs syndromeand primary biliary cirrhosis overlap. J. Eur. Acad. Dermatol. Venereol.2002; 16(3): 276–279.

15. Rhew E.Y., Barr W.G. Scleroderma renal crisis: new insights anddevelopments. Curr. Rheumatol. Rep. 2004; 6(2): 129–136.

16. Steen V.D., Medsger T.A. Jr., Osial T.A. Jr. et al. Factors predictingdevelopment of renal involvement in progressive systemic sclerosis. Am. J.Med. 1984; 76(5): 779–786.

17. DeMarco P.J., Weisman M.H., Seibold J.R. et al. Predictors and outcomesof scleroderma renal crisis. The high-dose versus low-dose D-penicillaminein early diffuse systemic sclerosis trial. Arthritis and rheumatism. 2002;46(11): 2983–2989.

18. Domsic R.T., Rodriguez-Reyna T., Lucas M. et al. Skin thickness progressionrate: a predictor of mortality and early internal organ involvement in diffusescleroderma. Ann. Rheum. Dis. 2010 Aug 2. [Epub ahead of print].

19. Avouac J., Walker U., Tyndall A. et al. Characteristics of joint involvementand relationships with systemic inflammation in systemic sclerosis: resultsfrom the EULAR Scleroderma Trial and Research Group (EUSTAR)database. J. Rheumatol. 2010; 37(7): 1488–1501.

20. Yamanishi Y., Yamana S., Ishioka S., Yamakido M. Development ofischemic colitis and scleroderma renal crisis following methylprednisolonepulse therapy for progressive systemic sclerosis. Intern. Med. 1996;35(7): 583–586.

21. Steen V.D., Medsger T.A. Case-control study of corticosteroids and otherdrugs that either precipitate or protect from the development of sclerodermarenal crisis. Arthritis and Rheumatism. 1998; 41(9): 1613–1619.

22. Lee S., Lee S., Sharma K. The pathogenesis of fibrosis and renal disease inscleroderma: recent insights from glomerulosclerosis. Curr. Rheumatol. Rep.2004; 6(2): 141–148.

23. Аникина Н.В., Гусева Н.Г., Мач Э.С. Нарушения микроциркуляции вгенезе склеродермической нефропатии. Тер. арх.1986; 8: 62–65.

24. Casoli P., Carretti C., Tumiati B. Scleroderma renal crisis as a possiblecomplication of cyclosporin A withdrawal. Clin. Rheumatol. 1994; 13(1):126–128.

25. Attoussi S., Faulkner M.L., Oso A., Umoru B. Cocaine-induced sclerodermaand scleroderma renal crisis. South Med. J. 1998; 91(10): 961–963.

26. Grobner T., Prischl F.C. Gadolinium and nephrogenic systemic fibrosis.Kidney Int. 2007; 72(3): 260–264.

27. Lim Y.L., Lee H.Y., Low S.C. et al. Possible role of gadolinium innephrogenic systemic fibrosis: report of two cases and review of theliterature. Clin. Exp. Dermatol. 2007; 32(4): 353–358.

28. Mouthon L., Mehrenberger M., Teixeira L. et al. Endothelin-1expression in scleroderma renal crisis. Hum. Pathol. 2010 Oct 22.[Epub ahead of print].

29. Canavese C., Mereu M.C., Aime S. et al. Gadolinium-associatednephrogenic systemic fibrosis: the need for nephrologistsc awareness. J.Nephrol. 2008; 21(3): 324–336.

30. Grobner T., Prischl F.C. Patient characteristics and risk factors fornephrogenic systemic fibrosis following gadolinium exposure. Semin. Dial.2008; 21(2): 135–139.

31. Lee S., Lee S., Sharma K. The pathogenesis of fibrosis and renal disease inscleroderma: recent insights from glomerulosclerosis. Curr. Rheumatol. Rep.2004; 6(2): 141–148.

32. Ichikawa H., Amano T., Fukuda S. et al. A case of scleroderma renalcrisis with massive pericardial effusion and positivity on antiphospholipidantibody test. Nippon Jinzo Gakkai Shi. 1998; 40(4): 295–300.

33. Katrib A., Sturgess A., Bertouch J.V. Systemic sclerosis and antineutrophilcytoplasmic autoantibody-associated renal failure. Rheumatol. Int. 1999;19(1-2):61–63.

34. Kamen D.L., Wigley F.M., Brown A.N. Antineutrophil cytoplasmicantibody-positive crescentic glomerulonephritis in scleroderma – a differentkind of renal crisis. J. Rheumatol. 2006; 33(9):1886–1888.

35. Anders H.J., Wiebecke B., Haedecke C. MPO-ANCA-Positive crescenticglomerulonephritis: a distinct entity of scleroderma renal disease? Am. J.Kidney Dis. 1999; 33(4): e3.

36. Idee J.M., Port M., Medina C. et al. Possible involvement of gadoliniumchelates in the pathophysiology of nephrogenic systemic fibrosis: a criticalreview. Toxicology. 2008; 248(2–3): 77–88.

37. Bonnet F., Longy-Boursier M., Aparicio M. et al. Scleroderma renal crisis.7 cases and review of the literature. Ann. Med. Interne (Paris). 1998;149(5): 243–250.

38. Herndon T.M., Kim T.T., Goeckeritz B.E. et al. Alveolar hemorrhage andpulmonary hypertension in systemic sclerosis: a continuum of sclerodermarenal crisis? J. Clin. Rheumatol. 2001; 7(2): 115–119.

39. Naniwa T., Banno S., Takahashi N. et al. Normotensive sclerodermarenal crisis with diffuse alveolar damage after corticosteroid therapy. Mod.Rheumatol. 2005; 15(2):134–138.

40. Гусева Н.Г. Системная склеродермия и псевдосклеродермическиесиндромы. М., Медицина, 1993.

41. Gibney E.M., Parikh C.R., Jani A. et al. Kidney transplantation forsystemic sclerosis improves survival and may modulate disease activity. Am.J. Transplant. 2004; 4(12): 2027–2031.

42. Гусев Н.Г., Аникина Н.В., Щербаков А.Б. Применение каптоприла присистемной склеродермии. Тер. арх. 1992; 64(5): 100–102.

43. Steen V.D., Costantino J.P., Shapiro A.P., Medsger T.A. Jr. Outcomeof renal crisis in systemic sclerosis: relation to availability of angiotensinconverting enzyme (ACE) inhibitors. Ann. Intern. Med. 1990; 113(5):352–357.

44. Gliddon A.E., Dore C.J., Black C.M. et. al. Prevention of vascular damagein scleroderma and autoimmune Raynaudcs phenomenon: a multicenter,randomized, double-blind, placebo-controlled trial of the angiotensinconvertingenzyme inhibitor quinapril. Arthritis Rheum. 2007; 56(11):3837–3846.

45. DeMarco P.J., Weisman M.H., Seibold J.R. et al. Predictors and outcomesof scleroderma renal crisis: the high-dose versus low-dose D-penicillaminein early diffuse systemic sclerosis trial. Arthritis Rheum. 2002; 46(11):2983–2989.

46. Wigley F.M., Korn J.H., Csuka M.E. et al. Oral iloprost treatment inpatients with Raynaudcs phenomenon secondary to systemic sclerosis: amulticenter, placebo-controlled, double-blind study. Arthritis Rheum. 1998;41(4): 670–677.

47. Airo P., Rossi M., Scarsi M. et al. Disease-modifying effects of long-termcyclic iloprost therapy in systemic sclerosis. A retrospective analysis andcomparison with a control group. Clin. Exp. Rheumatol. 2007; 25(5):722–727.

48. Steen V.D., Medsger T.A. Changes in causes of death in systemic sclerosis,1972-2002 Ann.Rheum.Dis. 2007; 66(7): 940–944.

49. Teixeira L., Mouthon L., Mahr A. et al. Mortality and risk factors ofscleroderma renal crisis: a French retrospective study of 50 patients. Ann.Rheum. Dis. 2008; 67(1): 110–116.

50. Walker J.G., Ahern M.J., Smith M.D. et al. Scleroderma renal crisis: pooroutcome despite aggressive antihypertensive treatment. Intern. Med. J.2003; 33(5-6): 216–220.

Похожие статьи

Бионика Медиа